Verastem Inc. | Ownership

Companies that own Verastem Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Consonance Capital Management LP
7,166,666
9.74%
7,166,666
3.82%
06/30/2018
Fidelity Management & Research Co.
4,058,097
5.51%
3,903,218
0%
06/30/2018
BlackRock Fund Advisors
3,279,050
4.46%
2,305,852
0%
06/30/2018
The Vanguard Group, Inc.
2,493,921
3.39%
651,214
0%
06/30/2018
BVF Partners LP
2,242,353
3.05%
-494,647
1.51%
06/30/2018
Eastern Capital Ltd.
1,967,857
2.67%
0
6.41%
11/06/2017
Renaissance Technologies LLC
1,066,400
1.45%
-289,600
0.01%
06/30/2018
SSgA Funds Management, Inc.
877,435
1.19%
840,014
0%
06/30/2018
LSP Advisory BV
874,857
1.19%
148,359
24.28%
06/30/2018
Northern Trust Investments, Inc.
596,828
0.81%
501,836
0%
06/30/2018

About Verastem

View Profile
Address
117 Kendrick Street
Needham Massachusetts 02494
United States
Employees -
Website http://www.verastem.com
Updated 07/08/2019
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer.